Business Wire

Takeda and The New York Academy of Sciences Announce 2024 Innovators in Science Award Winners

Share

Takeda (TSE:4502/NYSE:TAK) and The New York Academy of Sciences today announced the winners of the 2024 Innovators in Science Award for their excellence in, and commitment to, innovative science that has significantly advanced the field of research in cancer immunology. Each winner receives an unrestricted prize of USD 200,000.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231205723166/en/

The 2024 Senior Scientist winner is Robert D. Schreiber, Ph.D., the Andrew M. and Jane M. Bursky Distinguished Professor of Pathology and Immunology and director of The Bursky Center for Human Immunology and Immunotherapy at Washington University in St. Louis. Dr. Schreiber is an international leader in the fields of tumor immunology and cytokine biology. His early work was foundational in characterizing the role of cytokines in promoting immune responses to cancer. Dr. Schreiber pioneered the concept of “cancer immunoediting,” which describes how the immune system can induce, promote and prevent cancer. He also identified a novel subset of immune cells that interfere with cancer immunotherapy.

“I began researching the connection between the immune system and cancer more than 40 years ago. Along the way my research has benefitted from the contributions of more than 70 colleagues, technicians and trainees who have helped build on both our small discoveries and setbacks to make connections that are now transforming cancer research and treatment,” said Dr. Schreiber. “Scientific research is rewarding even when it takes decades to see results, which is why this award is so meaningful to me.”

The 2024 Early-Career Scientist winner is Elham Azizi, Ph.D., assistant professor of biomedical engineering, and the Herbert and Florence Irving Assistant Professor of Cancer Data Research at Columbia University. Dr. Azizi is recognized for developing a suite of computational tools and models that leverage artificial intelligence and machine learning to characterize immune profiles in the tumor microenvironment. Her novel machine learning algorithms are applied to data from genomic and imaging technologies, guiding improved and personalized cancer therapies. Dr. Azizi’s work has helped identify immune components involved in anti-tumor responses and characterize immune states that promote tumor progression and response to immunotherapy. Her innovative models have identified, for the first time, determinants of immunotherapy response in leukemia.

“This award is a significant recognition of our efforts to push the boundaries of cancer immunology through innovations in statistical machine learning,” said Dr. Azizi. “The Innovators in Science Award motivates me, my team and the broader community to continue on the path of blending multiple fields to find creative cancer immunology solutions. This award will allow me and my team to forge new collaborations and explore high-risk and ambitious directions in our mission to help patients.”

“We are inspired by the groundbreaking work of Dr. Schreiber and Dr. Azizi to deepen our understanding of both the immune response to cancer and immunotherapies,” said Andrew Plump, M.D., Ph.D., president of research & development at Takeda. “There has been remarkable progress in treating cancer with immunotherapies, thanks to the advances of these researchers and others. Takeda proudly supports the Innovators in Science Award to honor researchers who share in our goal to improve lives through the relentless pursuit of science.”

“Cancer is the second-leading cause of death worldwide. We are proud to join Takeda to champion pioneering medical researchers around the world who seek to harness the power of the body’s own immune system to fight cancer,” said Nicholas Dirks, president and chief executive officer of The New York Academy of Sciences. “The 2024 Innovators in Science Award winners are using AI, computational tools and groundbreaking methods to fight cancer and advance the field of cancer immunology. We congratulate the winners and eagerly await their future discoveries.”

The 2024 winners will be honored at the Innovators in Science Award ceremony and symposium in April 2024 in Boston. For more information, visit TakedaInnovators.com.

About the Innovators in Science Award
Established in 2016, the Innovators in Science Award grants two unrestricted prizes of USD 200,000 each award cycle: one to an early-career scientist and the other to a well-established senior scientist who have distinguished themselves for the creative thinking and impact of their research. The Innovators in Science Award is a limited submission competition in which research universities, academic institutions, government, or non-profit institutions, or equivalent from around the globe with a well-established record of scientific excellence are invited to nominate their most promising early-career scientists and their most outstanding senior scientists. The therapeutic focus rotates each year. The 2024 focus is cancer immunology. Prize winners are determined by a panel of judges, independently selected by The New York Academy of Sciences, with expertise in these disciplines. The New York Academy of Sciences administers the Award in partnership with Takeda. For more information, visit TakedaInnovators.com.

About Takeda
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

About The New York Academy of Sciences
The New York Academy of Sciences is an independent, not-for-profit organization that has been committed to advancing science for the benefit of society since 1817. With more than 20,000 Members in 100 countries, the Academy advances scientific and technical knowledge, addresses global challenges with science-based solutions, and sponsors a wide variety of educational initiatives at all levels for STEM and STEM-related fields. The Academy hosts programs and publishes content in the life and physical sciences, the social sciences, nutrition, artificial intelligence, computer science, and sustainability. The Academy also provides professional and educational resources for researchers across all phases of their careers. For more information, visit www.nyas.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
The New York Academy of Sciences
Kamala Murthy
Kmurthy@nyas.org

Takeda
Japanese Media
Yuko Yoneyama
yuko.yoneyama@takeda.com

U.S. and International Media
Kerry Bryant
kerry.bryant@takeda.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

itel Grand 2024 Brand Launch, the Industry's Biggest Event at the Egyptian Pyramids23.2.2024 20:35:00 EET | Press release

itel, the global leading smart life brand committed to providing affordable and good quality consumer electronic products, is poised to redefine its visual identity with the spectacular launch of its new logo at the iconic Great Pyramids of Giza in Egypt on February 22. This momentous occasion will not only mark a significant evolution in itel’s brand image but also serve as a platform to engage and celebrate with esteemed partners and customers worldwide, especially customers from the Middle East and North Africa region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240222762808/en/ itel successfully launched its 2024 brand launch event at Egyptian Pyramids (Photo: Business Wire) The unveiling ceremony at the Egyptian Pyramids signifies itel’s commitment not only to technological innovation but also to creating a memorable and immersive experience for attendees. The event will kick off with a breathtaking display of openin

Toshiba at EuroCIS: Delivering Solutions to Empower Retailers to Go Beyond23.2.2024 19:43:00 EET | Press release

At EuroCIS 2024, Toshiba Global Commerce Solutions showcases how retailers can “Create Beyond what’s Possible” to transform retail operations and customer experiences with its innovative solutions portfolio (booth in hall 9 #B42). The international trade fair will take place on February 27-29 in Düsseldorf, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240223284358/en/ At EuroCIS 2024, Toshiba Global Commerce Solutions will empower retailers to transform their operations and customer experiences with innovative solutions and services. (Photo: Business Wire) “Our unified commerce and self-service solutions help retailers create shopping experiences that go beyond consumer expectations,” says Meike Marquardt, Head of Marketing for Europe, Toshiba Global Commerce Solutions. “With Toshiba Global Commerce Solutions as a trusted partner, retailers have the power to adapt effortlessly to the rapidly changing business need

Adtran confirms compliance with final BABA ruling and continues US investment23.2.2024 19:40:00 EET | Press release

Adtran today announced its readiness to support the Broadband Equity Access and Deployment (BEAD) program, welcoming the clarity and guidance provided by the Build America, Buy America (BABA) rule. With its commitment to US-based manufacturing spanning three decades, Adtran is at the forefront of the market with BABA-compliant fiber access solutions ready to enhance nationwide connectivity, economic growth and the digital inclusivity of communities across America. With 42.5 billion USD allocated for grants, the BEAD program aims to connect millions of underserved homes in the USA to high-speed broadband and has a mandate for domestically produced equipment. Adtran will supply BABA-compliant optical line terminals (OLTs), cabinets, ONTs and pluggable optics, providing a comprehensive solution fully ready to meet the needs of the BEAD program. These offerings will soon be showcased on the NTIA’s certification website. This press release features multimedia. View the full release here: ht

Mavenir and Terrestar Solutions Partner to Accelerate Commercial Deployment of 5G New Radio Non-Terrestrial Network23.2.2024 18:49:00 EET | Press release

Mavenir, the cloud-native network infrastructure provider building the future of networks, continues its pioneering leadership in Open RAN with 5G New Radio (NR) Non-Terrestrial-Network (NTN) solutions. The latest initiative is to integrate satellite connectivity for Open RAN terrestrial networks thereby enabling seamless connectivity for users across satellite and terrestrial networks. The project is being delivered in collaboration with Terrestar Solutions, a Canadian based Satellite Operator. Satellite Operators are actively looking at ways to harness 5G NTN capabilities within their network topology, to extend coverage and capacity in areas where traditional terrestrial networks may be economically unfeasible or impractical. Terrestar will launch a new Narrowband IoT (NB-IoT) service offer to the market, evolving to a full 5G Direct to Device (D2D) service by 2025. As the chosen technology supplier, Mavenir will provide the enabling 3GPP standards-compliant Core and O-RAN interface

Vertex Receives CHMP Positive Opinion for KALYDECO® for the Treatment of Infants With Cystic Fibrosis Ages 1 Month and Older23.2.2024 15:10:00 EET | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants with cystic fibrosis (CF) ages 1 month to less than 4 months old who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Cystic fibrosis is a chronic, progressive disease that is present from birth, which is why it is important to treat the underlying cause of this disease as early as possible to potentially slow disease progression,” said Fosca De Iorio, Vice President, International Medical Affairs at Vertex. “If the label expansion for KALYDECO is approved, this would allow eligible infants with CF to receive a treatment that targets the underlying cause of their disease at the very start of their l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye